Fas (CD95) and bcl-2 expression in active skin lesions of Behçet's disease

Journal of the European Academy of Dermatology and Venereology

Volumn 19, Issue 5, 2005, Pages 569-572

  Baris Y S ^a   Yildiz, L ^a   Senturk N ^a   Kandemirt, B ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

bcl 2; Beh et's disease; CD95; Fas

Indexed keywords

FAS ANTIGEN; PROTEIN BCL 2;

ADOLESCENT; ADULT; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN BIOPSY; SKIN DEFECT; SKIN INFLAMMATION;

ADOLESCENT; ADULT; ANTIGENS, CD95; APOPTOSIS; BEHCET SYNDROME; BIOPSY, NEEDLE; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECURRENCE; RISK ASSESSMENT; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SKIN DISEASES; TISSUE CULTURE TECHNIQUES;

EID: 28644448862     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2005.01250.x     Document Type: Article

References (14)

1. Meador R, Ehrlich G, Feldt JM. Behçet's disease: immunopathologic and therapeutic aspects. Current Rheumatol Reports 2002; 4: 47-54.
2. International Study Group for Behçet's disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078-1080.
3. Elder D, Elenitsas R, Jaworsky C, Johnson B. Histopathology of the Skin, 8th edn. Lippincott-Raven, Philadelphia, 1997.
4. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Krosmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 22: 348 (6299): 334-336.
5. Lu QL, Abel P, Foster CS, Lalani EN. Bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol 1996; 27: 102-110.
6. Mountz JD, Wu J, Cheng J, Zhou T. Autoimmune disease: a problem of defective apoptosis. Arthritis Rheum 1994; 37: 1415-1420.
7. Nakamura S, Sugita M, Matoba H et al. Insufficient expression of Fas antigen on helper T cells in Behçet's disease. Br J Ophthalmol 1996; 80: 174-176.
8. Senturk N, Yildiz L, Sullu Y, Kandemir B, Turanli AY. Expression of bcl-2 protein in active skin lesions of Behçet's disease. Int J Dermatol 2001; 40: 747-750.
9. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-1455.
10. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-1462.
11. Miret C, Font J, Molina R et al. bcl-2 oncogene levels correlate with systemic lupus erythematosus disease activity. Anticancer Res 1999; 19: 3073-3076.
12. Hamzoi A, Hamzoi K, Kooli C et al. High levels of bcl-2 protein in T lymphocytes of patients with Behçet's disease. Clin Exp Rheumotol 1996; 14: 106-107.
13. Hamzaoui K, Hamzaoui A, Zakraoui L, Chabbou A. Levels of soluble Fas/Apo-1 in patients with Behçet's disease. Med Inflamn 1998; 7: 111-114.
14. Cheng J, Zhou T, Liu C et al. Protection from Fas-mediated apoptosis by a soluble form of Fas molecule. Science 1994; 263: 1759-1762.